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Glucose Sensing During Hypoglycemia:
Lessons From the Lab
S
hortlyaftertheintroductionofinsu-
lin in the management of type 1 di-
abetes, clinicians became aware of
thepotentialforinsulintherapytoinduce
iatrogenic hypoglycemia. Hypoglycemia
remainsthemajoradverseeffectofinsulin
therapy and has emerged as a signiﬁcant
limitation to achieving near-normal glu-
cose control, which is required to reduce
the risk of microvascular complications.
The average individual with type 1 diabe-
tes experiences around two episodes of
symptomatic hypoglycemia per week. In
the recent U.K. Hypoglycemia Study (1),
the incidence of severe hypoglycemia (re-
quiring external assistance) was 110 epi-
sodes per 100 patient-years in subjects
with duration of diabetes 5 years and
320 episodes per 100 patient-years in
subjects with duration of diabetes 15
years. Thus, despite the introduction of
insulin analogues and improved delivery
systems, hypoglycemia remains a major
concern for individuals with type 1 and
long-duration type 2 diabetes as well as
their caregivers.
When glucose levels fall, a sequence
of counterregulatory responses is trig-
gered, which mainly involves the sup-
pression of endogenous insulin secretion
and the release of counterregulatory hor-
mones that act rapidly to promote endog-
enous glucose production and limit
peripheral glucose utilization. As glucose
levels fall further, subjective awareness of
hypoglycemia results in behavioral
changes that ordinarily lead an individual
to seek food. In healthy individuals, this
homeostatic mechanism works well and
hypoglycemia is rare, but for individuals
with type 1 diabetes, these compensatory
systems are disrupted at every level. First,
for most individuals insulin delivery to
the systemic circulation following a sub-
cutaneous injection will continue despite
the development of hypoglycemia. Sec-
ond, almost all individuals with type 1
diabetes will over time develop defects in
the hormonal counterregulatory defense
against hypoglycemia. Within 5 years of
diagnosis of type 1 diabetes, hypoglyce-
mia fails to stimulate release of the major
counterregulatoryhormoneglucagon(2).
As a result, individuals with type 1 diabe-
tesareparticularlydependentonthesym-
pathoadrenal (primarily epinephrine and
norepinephrine) response to low blood
glucose. However, within 10 years of di-
agnosis, the majority of patients develop
additionalimpairmentsinsympathoadre-
nal and other neurohormonal responses
against hypoglycemia (2). In addition,
symptomawarenessbecomesimpairedin
individuals with type 1 diabetes. This
combination of disrupted physiological
and behavioral responses to hypoglyce-
mia markedly increases the risk of suffer-
ing severe hypoglycemia in patients with
type 1 diabetes.
To understand why glucose counter-
regulationisimpairedindiabetesrequires
a greater knowledge of where and how
hypoglycemia is sensed, how hypoglyce-
mia-sensitive cells trigger a counterregu-
latory response, and how the presence of
diabetes inﬂuences these mechanisms.
Research in this area has in recent years
focused on animal and more basic mod-
els,althoughthegroundworkforthiswas
laid by a series of elegant human studies
in the 1980s and 1990s. In this review, I
will examine the literature, largely based
on rodent studies, that is beginning to
shed some light on the mechanisms that
underpin hypoglycemia detection. This
review will focus on the role of the ven-
tromedial hypothalamus (VMH) (Fig. 1),
a key central glucose-sensing region in-
volved in the detection of hypoglycemia,
to illustrate the advances that have been
made in this ﬁeld of research.
The hypoglycemia sensors
Under most physiological conditions glu-
cose is the primary fuel for the brain. The
brain accounts for more than half the
body’sglucoseuseandbecausefuelstores
such as glycogen are limited, it is very de-
pendent on a continuous supply from the
circulation. This probably explains why
the glucose sensors thought to be domi-
nant during hypoglycemia are found in
the brain. Neurons shown to be regulated
by glucose have been found in a number
of brain areas that share certain common
features (3). Within the brain they local-
izetoregionsadjacenttotheIIIorIVven-
tricle or to the circumventricular organs
(these are regions of the brain where the
blood-brain barrier is leaky or absent).
This potentially allows glucose sensing
neurons direct sampling and, hence,
monitoring of glucose levels in the blood,
brain, and cerebrospinal ﬂid. This is im-
portant because the presence of the
blood-brain barrier ensures that brain
glucose levels are only 10–30% of the
levels seen in the blood (4). Thus, glu-
cose-sensing neurons are able to integrate
changes in glucose within each of these
different regions.
The VMH was shown to play a signif-
icant role in the detection of insulin-
induced hypoglycemia in a series of in
vivo rodent studies in the 1990s. Borg et
al. (5) were able to demonstrate that
chemical destruction of the VMH in a ro-
dent model with ibotenic acid caused
75% reduction in the hormonal coun-
terregulatory response to acute hypogly-
cemia. Subsequently, they showed that
thelocalperfusion,usingmicrodialysisin
awakeunrestrainedrats,oftheVMHwith
2-deoxyglucose (a nonmetabolizable
form of glucose that effectively causes lo-
cal hypoglycemia) stimulated a classic
systemic counterregulatory response (6).
Finally, and perhaps most convincingly,
theydemonstratedagainwithmicrodialy-
sis that local perfusion of the VMH with
glucose,maintainingglucoselevelsinthis
select brain region during systemic insu-
lin-induced hypoglycemia, markedly
suppressed the hormonal counterregula-
tory response (7). The addition of tracer
to the perfusate (6), as well as the lesion
studies (5), conﬁrmed that the interven-
tioninthesestudieswaslocaltotheVMH.
In addition, a number of electrophysio-
logical studies from hypothalamic slice
preparations have shown that the VMH
contains neurons that respond directly to
low glucose (8), as do dissociated VMH
neurons (9). Finally, transgenic mice that
lack the vesicular glutamate transporter
VGLuT2 selectively in steroidogenic fac-
tor-1 (SF1) neurons, which in rodents are
only expressed in the VMH, show mark-
edly impaired counterregulatory hor-
monalresponsestoacuteinsulin-induced
hypoglycemia (10). Taken together these
studies all point toward the VMH playing
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which the brain detects a falling glucose
andtriggersacounterregulatoryhormone
response.
For normal glucagon and epineph-
rine counterregulation to occur, neural
pathwaysmustexistbetweentheglucose-
sensing regions of the brain such as the
VMH and the pancreatic -cell and adre-
nal medulla, respectively. These path-
ways have not yet been fully elucidated.
However, using pseudorabies virus as a
retrograde tracer, Buijs et al. (11) were
able to characterize sympathetic and
parasympathetic inputs to the pancreas.
In this neuroanatomical study, the VMH
was identiﬁed as a third-order neuron
(the last of three neurons in a pathway
that ultimately leads to the discharge of a
neurotransmitter into the synaptic cleft)
innervating the pancreas by way of other
nuclei in the hypothalamus and thalamus
and, subsequently, the dorsal motor nu-
cleus of the vagus (parasympathetic) and
intermediolateral cell column (sympa-
thetic) (Fig. 1). These studies provide a
potential neural pathway through which
VMH glucose-sensing neurons could ini-
tiate glucose counterregulation during
hypoglycemia, although why, given the
major role that the VMH appears to play
in coordinating the counterregulatory re-
sponse in vivo, this should be an indirect
one is not clear. It should also be pointed
out that if the VMH is not a primary sens-
ing region but rather an important relay
station for other brain regions, then this
pathway may be even more indirect.
Glucose-sensing neurons are not
unique to the brain and have also been
identiﬁed in the intestine, hepatoportal
vein, and carotid body as well as the clas-
sic glucose sensor the pancreatic -cell
(3). The hepato-portal glucose sensor in
particular appears to play a signiﬁcant
Figure 1—Neural pathways linking the VMH via sympathetic and parasympathetic neurons to the pancreas. Retrograde neuronal tracer studies
using pseudorabies virus microinjected into the pancreas of the rats established the VMH as a third-order neuron reaching the parasympathetic and
sympathetic innervation of the pancreas via the paraventricular hypothalamic nucleus (PVN) and interomediolateral (IML) nucleus as well as the
dorsal motor nucleus of the vagus (DMV), respectively. The dorsomedial hypothalamus (DMH) and lateral hypothalamus (LHA) also feed into this
pathwayaswellasthenucleustractussolitarius(NTS)inthehindbrain,eachofwhichplaysaroleonglucosesensing.Thenucleustractussolitarius
also is the likely point of integration of inputs from peripheral sensors via vagal afferents (X). Reprinted with permission from Buijs et al. (11).
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and links to central glucose sensors via
capsaicin-sensitive sensory neurons (13).
It is interesting to speculate whether both
centralandperipheralsensorsmayforma
neural network of glucose-sensing cells
designed to monitor and maintain glu-
cose homeostasis. Certainly, evidence of
presynaptic regulation of VMH glucose-
sensing neurons by glucose-sensing neu-
rons in other brain regions has been
demonstrated(14).Moreover,andpartic-
ularly in the brain, glucose-sensing neu-
rons are generally located in areas
involved in the control of the autonomic
nervous system, neuroendocrine func-
tion,nutrientmetabolism,andenergyho-
meostasis. What this effectively means is
that brain glucose-sensing neurons are
abletoreceiveinputsfrombloodnutrient
levels,avarietyofendocrinehormones,as
well as from numerous peripheral and
central sensory systems.
Mechanisms of glucose sensing
The deﬁning feature of a glucose-sensing
neuron is that it can use glucose not sim-
ply as a fuel but as a signaling molecule
thatregulatesitsactivity.Suchspecialized
neurons were ﬁrst demonstrated by Oo-
mura et al. (15) in 1969. These neurons
are glucose sensing in so far as glucose is
the major metabolic substrate for the
brain, but the fact that these neurons can
use other fuels such as lactate produced
either by astrocytes (16) or delivered lo-
cally (17) to alter their function suggests
that it is more likely glucose oxidation–
derived intracellular ATP that determines
the activity of these neurons. This is in-
triguing because neuronal levels of ATP
are generally thought to be well main-
tained, which means that there would
need to be subcellular compartmentaliza-
tion of the glucose-sensing apparatus to
provide sensing capability. Such com-
partmentalization has been shown within
pancreatic -cells (18).
The VMH, like other central glucose-
sensing regions, has been shown to con-
tain neurons whose activity is altered in
response to changes of glucose within the
physiological range. Two predominant
subtypesofglucose-sensingneuronshave
been identiﬁed: namely, glucose-excited
(GE) neurons whose activity increases as
glucose levels rise and glucose-inhibited
(GI) neurons whose activity decreases as
glucose levels rise (8). The prevailing the-
oryintheﬁeldatthemomentisthatthese
neurons use sensing mechanisms very
similartothosefoundinthepancreatic-
and-cells(19).Inthisparadigm,theGE
neuron is analogous to the pancreatic
-cellwhereastheGIneuronbehaveslike
the -cell (Fig. 2).
The VMH -cell
Insulin secretion from the pancreatic
-cell follows membrane depolarization,
which in turn is a response to a rise in
glucose within the islet. Key steps in this
process are though to be 1) entry of glu-
cose into the -cell via the high-capacity
GLUT (GLUT2) to allow rapid equilibra-
tionofextracellularandcytosolicglucose;
2)phosphorylationofglucosebythelow-
afﬁnity hexokinase, glucokinase, linking
changesinextracellularglucosewithpro-
portional changes in the cytosolic ATP:
ADPratio;and3)closureofATP-sensitive
K
 channel (KATP) in the plasma mem-
brane of metabolism that leads to depo-
larizationandincreasedelectricalactivity.
Thereissomesupportforthismechanism
being resent in VMH GE neurons.
GLUT2, glucokinase, and the Kir6.2 sub-
unit of the KATP channel are expressed in
some but not all VMH GE neurons (9).
Electrophysiological studies suggest glu-
cokinase plays a regulatory role in VMH
GE neuron sensing ability (20), whereas
selective downregulation of glucokinase
in primary VMH neuronal cultures led to
the loss of all demonstrable glucose-
sensing activity (21). In addition, in vivo
microinjection of glucokinase activators
or selective downregulation of VMH glu-
cokinase modiﬁes the counterregulatory
response to acute hypoglycemia (22).
Similarly, KATP channels have been
demonstrated throughout the brain, in-
Figure2—HypotheticalsensingmechanismofGE(A)andGI(B)neurons.GlucoseenterstheGE
neuronthroughGLUT2orGLUT3andisphosphorylatedbyglucokinase,actingasthegatekeeper
andregulatingtheproductionofcytosolicATPinasubcellularcompartment.TheATPclosesKATP
channels in the plasma membrane causing depolarization. In turn, this leads to Ca
2 inﬂux
through voltage-dependent calcium channels (VDCC), stimulating neurotransmitter release
and/or increased action potential frequency. Lactate, produced locally by astrocytes or arriving
systemically, enters the neuron via monocarboxylate transporter-2 (MCT2) and can then be
metabolized to form ATP. In GI neurons, glucokinase may once again act as the gatekeeper. A
falling glucose results in an increase in the AMP:ATP ratio activating AMPK and stimulates the
formation of NO, which may diffuse out to adjacent glial cells or act as a neurotransmitter. In
addition, AMPK may act on chloride (Cl) channels leading to neuronal depolarization and neu-
rotransmitter release and/or increased action potential frequency.
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beinvolvedinglucosesensing(23).Using
single-cell RT-PCR to analyze glucose-
sensing neurons (identiﬁed electrophysi-
ologically in a hypothalamic slice
preparation), investigators have shown
they express mRNA for Kir6.2 and sul-
fonurea receptor-1 (SUR1), the two sub-
units that comprise the KATP channel in
the pancreatic -cell (9). In addition,
electrophysiologicalstudiesinrat(20,24)
and mouse (25) VMH have demonstrated
that sulfonylureas (agents that block the
KATP channel) can alter the response of
GE neurons to changes in ambient glu-
cose,andKir6.2knockoutmiceshowim-
paired glucose counterregulation to
systemic hypoglycemia (25). Finally, in
vivo perfusion of VMH of rodents with
glibenclamide (a KATP channel blocker)
suppresses (26) whereas diazoxide (a
KATP channel opener) ampliﬁes (27) hor-
monal counterregulatory responses to
acute hypoglycemia.
These studies provide support for the
-cell model, but inconsistencies in the
literature are apparent that mean this hy-
pothesis is not yet established. For in-
stance, extracellular levels of glucose in
the brain are only about 10–30% of the
levels found in blood. Microdialysis stud-
iesinrats(4,28)andhumansubjects(29)
have shown that the extracelullar ﬂuid
(ECF)glucoselevelstowhichneuronsare
exposed are in the range of 1–2 mmol/l
under basal conditions and fall markedly
during acute hypoglycemia (0.5
mmol/l) (30). This means that during hy-
poglycemia, brain ECF glucose levels are
well beneath the range in which glucoki-
nase or GLUT2 usually act in a regulatory
manner. In addition, using genetically
targeted luciferases to monitor cytosolic
ATP, Ainscow et al. (31) were unable to
detect a rise in ATP during exposure of
hypothalamic neurons to a high glucose,
although they were able to see increased
cytosolicATPin-cells,hypothalamicas-
troglia, and cerebeller neurons. Interest-
ingly, transgenic mice that express
GLUT2 only in astroglial cells in the cen-
tral nervous system are rescued from the
defect in counterregulation seen in whole
bodyGLUT2
/mice(32),raisingthein-
triguing possibility that astroglial cells
might function as detectors of extracellu-
lar glucose change. Tanycytes, which are
specialized glial cells that line the dorsal
lateral, ventral lateral, and ﬂoor of the
third ventricle express GLUT2; glucoki-
nase;andtheKATPchannelsendlongpro-
cesses that terminate in the VMH (33).
Burdakovetal.(34)haveproposedtwo
further possibilities through which glucose
mightactivateglucose-sensingneuronsthat
donotinvolvethemetabolismofglucose.In
the ﬁrst, glucose transport is coupled di-
rectly with the transmembrane movement
of ions, such as those used by sodium-
glucose cotransporters (SGLTs). In this
way, an inward current is generated while
glucose is transported into the neuron, and
this leads to depolarization and increased
excitability. Phloridizin, a nonselective in-
hibitor of SGLTs, inhibits glucose-induced
excitation of VMH neurons (20). Alterna-
tively, glucose might bind to an extracellu-
lar receptor that could alter electrical
activity without transporting the glucose
into the neuron (34). Recently, such a
mechanism has been demonstrated in GI
orexigenic neurons in the lateral hypothal-
amus (35).
Onceachangeinglucoseissensedby
the GE neuron, it needs to then commu-
nicatethatsignaltoadownstreamneuron
in the pathway that leads eventually to
glucose counterregulation. In general,
neural communication relies on the re-
lease of classic neurotransmitters such as
GABA, neuropeptides, or unconventional
transmitterssuchasnitricoxide(NO).No
deﬁnitive transmitter has been identiﬁed
for GE neurons; it is very possible that a
number of transmitters and peptides are
important, but most current data support
a role for the inhibitory neurotransmitter
GABA. GAD, the rate-limiting enzyme in
GABA synthesis, is expressed in 56% of
GE and 36% of GI neurons (9). In vivo
antagonism of the VMH GABA receptor
ampliﬁes the counterregulatory hormone
responsetoacutehypoglycemia(36),and
VMH GABA release is regulated by KATP
channel modulation (37). Finally, GABA
tone in the VMH is increased following
recurrent hypoglycemia (38).
The VMH -cell
GI neurons show a decrease in activity
as glucose levels rise (8). It is perhaps
easier to think of GI neurons as those
glucose-sensing neurons that become
more active when glucose levels fall,
and as such they may use signaling
mechanisms more relevant to the pan-
creatic -cell. Unfortunately, like the
-cell, the signaling pathways used by
the GI neuron are not well understood.
This may reﬂect the fact that they ap-
pear to be few in number, comprising
only 3–14% of neurons in the VMH nu-
cleus(14,39).Althoughrecentevidence
suggests GI neurons may be more prev-
alent, when improved slice techniques
are used in conjunction with novel
methods for identifying GI neurons
(e.g., membrane potential dyes) as
manyas30–40%ofallneuronsinthe
VMH are reported to be GI neurons
(40).
Current evidence favors a role for
AMP-activated protein kinase (AMPK) in
the sensing pathway used by GI neurons.
AMPK has been described as an intracel-
lular fuel gauge in that it is activated in
response to a rise in the intracellular ratio
ofAMP:ATPandactstoswitchoffenergy-
consuminganabolicprocessesandswitch
on energy-producing catabolic processes
(41). Canabal et al. (40) demonstrated
that in VMH GI neurons exposed to 2.5
mmol/l glucose, AICAR (an activator of
AMPK) mimicked the excitatory effect of
lowglucose(0.5mmol/l)onactionpoten-
tial frequency. Both low glucose and
AICAR were shown to mediate their ef-
fects, in part, through an increase in NO
production in GI neurons. Conversely,
increased NO production in response to
lowglucosewasblockedbycompoundC,
an inhibitor of AMPK (40). In a related
series of studies, Mountjoy et al. (42) re-
ported that activation of AMPK with
AICAR or inhibition with compound C
altered neuronal activity in GI but not GE
neurons in an ex vivo hypothalamic cell
culture system obtained from the medio-
basal(includingVMHandArc)hypothal-
amus. In this study, AMPK had no effect
on the KATP channel (42), but others have
suggested AMPK may instead act on a
chloridechanneltodepolarizetheplasma
membrane(43).Inrodentstudies,invivo
pharmacological activation of AMPK in
the VMH during acute hypoglycemia am-
pliﬁes the glucose counterregulatory re-
sponse in normal Sprague-Dawley rats
(44) and restores the hormonal counter-
regulatory response to hypoglycemia in
rats with defective counterregulation
(45). Conversely, downregulation of
AMPK in the VMH using speciﬁc RNA
interference suppresses the counterregu-
latory response to acute hypoglycemia
(46). In addition, mice that selectively
lack the -catalytic subunit of AMPK in
proopiomelanocortin or agouti gene–
related protein neurons (both neuronal
types are located in the medio-basal hy-
pothalamus and are involved in feeding
behavior and energy homeostasis) lose
the responsiveness of these neurons to
changes in extracellular glucose (47).
AsintheGEneuron,themodeofneu-
rotransmission in GI neurons has yet to be
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nephrinetothehypothalamusincreasescir-
culating glucose and counterregulatory
hormones, whereas norepinephrine recep-
tor antagonists block the counterregulatory
response to 2-deoxyglucose (DG) (48).
Glucoprivationinducedthrough2-DG(49)
or insulin (50) increases VMH norepineph-
rine levels, whereas local perfusion of the
VMH with glucose during systemic hypo-
glycemia prevents the local increase in nor-
epinephrine (51). Intriguingly, terminals
from noradrenergic neurons form a shell
around the VMH, implying that the detec-
tion of hypoglycemia by these neurons
takes place at a site distant from the VMH.
Brainstem norepinephrine cell groups, for
instance, which respond to glucoprivation,
project to the VMH and may ultimately
formaneuralcircuitthroughwhichperiph-
eralandhypothalamicglucosesensorsinte-
grate (52).
Additionally,apotentialrolefortheex-
citatory transmitter glutamate recently has
been revealed. Neurons in the VMH are
largely glutaminergic and express high lev-
els of the vesicular glutamate transporter
VGLuT2. Mice lacking VGLuT2 selectively
in steroidogenic factor-1 (a transcription
factor unique to a population of VMH neu-
rons)neuronsshowamarkedlysuppressed
counterregulatory response to hyperinsu-
linemic hypoglycemia (10). These ﬁndings
support a potential role for excitatory glu-
taminergictransmissionintheoutputsignal
from VMH GI neurons. Finally, the uncon-
ventional transmitter NO may also play a
role in GI neuron signaling (40).
Recurrent hypoglycemia and glucose
sensing
Studies in rodent models suggest that re-
current hypoglycemia results in altered
glucose sensing within the brain. Recur-
rent hypoglycemia lowers the glucose
level at which activation of glucose-
inhibited neurons in the VMH is initiated
(53). Moreover, in vivo activation of
AMPK in the VMH of rats that have expe-
riencedpriorrecurrenthypoglycemiacan
restore hormonal counterregulatory re-
sponses to a subsequent hypoglycemic
challenge(45).Similarly,openingofKATP
channelsintheVMHofrecurrentlyhypo-
glycemic rats leads to the restoration of
normal counterregulatory responses to
subsequent hypoglycemia (27).
There are a number of potential ex-
planations for altered glucose sensing in
the VMH following recurrent hypoglyce-
mia. One possibility is that glucose sens-
ing neurons are seeing higher glucose
and/or ATP levels during a subsequent
hypoglycemic challenge caused by an in-
creased supply of fuel through altered
glucose or alternate fuel transport. How-
ever, whereas these changes suggest an
increased capacity to transport fuels
across the blood-brain barrier and into
glucose-sensing neurons, the data from
human studies have been mixed with
some indicating increased whole brain
glucose, or acetate, uptake after chronic
hypoglycemia and others showing no
change (3). Alternatively, the VMH might
obtain additional metabolic substrates
from more local sources. Brain glycogen
can act as a fuel reserve during acute hy-
poglycemia (54), and brain glycogen lev-
elsmayactuallyincreaseinresponsetoan
acute episode of hypoglycemia (54). Gly-
cogen supercompensation could provide
an additional fuel reserve that leads to de-
fectiveglucosesensingduringasubsequent
episode of hypoglycemia. However, brain
glycogenlevelsappeartobeverylowandin
rodentsreturntobaselinelevelswithin24h
of a hypoglycemic episode (55).
It has also emerged that within the
brain there exist mechanisms for regulating
the magnitude of the neuroendocrine re-
sponse to acute hypoglycemia. The cortico-
trophin-releasinghormone(CRH)familyof
ligands and receptors form an ancient and
highly conserved means of regulating the
neuroendocrinestressresponse.Atkeysites
involved with autonomic activation within
the brain, CRH acting through the CRH re-
ceptor (CRHr)-1 appears to lead to an am-
pliﬁcation of the autonomic response to
stress, whereas urocortin (part of the CRH
family of peptides) acting through the
CRHr2 receptor suppresses the autonomic
response to stress (56). We recently were
able to show that such a mechanism oper-
ated in the VMH with urocortin locally de-
livered to the VMH markedly suppressing
thecounterregulatoryresponsetoacutehy-
poglycemia (57), whereas CRH ampliﬁed
theresponse(58).Thus,analterationinthe
balance between those mechanisms that
regulate the hypoglycemia stress re-
sponsemightcontributetothedevelop-
ment of defective counterregulation.
If our model is correct, these studies
suggest that the balance between GE and
GI neuronal activity is altered by recur-
rent hypoglycemia. The important point
here is that both the GE and GI neurons
operateoverarangeofglucosevaluesand
therefore are not either on or off but
rather the balance tips in favor of one or
other population as the glucose levels
ﬂuctuate. We would anticipate that GE
neurons (acting to suppress counterregu-
lation) are more likely to be active and/or
GI neurons (acting to amplify counter-
regulation) less likely to be active follow-
ing recurrent hypoglycemia. Consistent
with this hypothesis, there is increased
GABAergic inhibitory tone (38) (hypo-
thetically GE mediated) and reduced
AMPK activity (59) (hypothetically GI
mediated) in the VMH following recur-
rent hypoglycemia, the net effect being
that full glucose counterregulation is ini-
tiated at a lower glucose level. This gives
individuals less time to react to, and seek
treatment for, hypoglycemia.
SUMMARY— Within the body a
number of highly specialized regions
sense alterations in glucose levels and, in
thecaseofhypoglycemia,thisleadstothe
generation of a glucose counterregulatory
defense response. The VMH, discussed in
detail in this article, reﬂects only one of a
number of brain regions thought to be
important in the detection of hypoglyce-
mia,andtogetherthesebrainregionsmay
form an integrated neural network coor-
dinating physiological and behavioral re-
sponses to a hypoglycemic challenge.
Glucose-sensing neurons, by virtue of
speciﬁc sensing systems, directly or indi-
rectly translate the rate or quantity of glu-
cose oxidation into a neural signal that
altersneuronalﬁringrates.Theseneurons
appear to use signaling mechanisms that
parallel those used by pancreatic - and
-cells. The GE neuron, more likely to
operate under conditions of euglycemia
orhyperglycemia,mayuseglucokinaseas
its key regulatory step and the KATP chan-
nel to then translate that signal into al-
tered neuronal ﬁring rates. In contrast,
the GI neuron, active under hypoglyce-
mic conditions, may be dependent on al-
terations in intracellular AMPK activity
that, in turn, may act via NO to alter neu-
ronalﬁringrates.Potentially,thecounter-
balance between GI and GE neuronal
activity forms the most sensitive means of
regulatingandmaintainingbloodglucose
within a narrow physiological range as
well as ensuring an adequate supply of
glucose to the brain. Recurrent exposure
to hypoglycemia disturbs this relation-
ship in a number of ways, which may in-
clude an increased capacity of glucose-
sensingregionsofthebraintouseglucose
and/or alternate fuels, as well as changes
in both the mechanisms that sense glu-
coseandthosethatﬁne-tunethehypogly-
cemic stress response, the net effect being
McCrimmon
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terregulation is initiated.
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